FDA Engagement And XPERIENCE Will Secure Future Confidence

AN
AnalystConsensusTarget
Consensus Narrative from Analysts
Published
15 Apr 25
Updated
20 May 25
AnalystConsensusTarget's Fair Value
AU$0.27
46.1% undervalued intrinsic discount
20 May
AU$0.14
Loading
1Y
-40.8%
7D
0%

Author's Valuation

AU$0.3

46.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25
Fair value Increased 0.30%

AnalystConsensusTarget has increased revenue growth from 18.2% to 43.6% and decreased future PE multiple from 17.7x to 9.8x.